Cargando…
Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy
Induced pluripotent stem cells (iPSCs) are promising candidate cells for cardiomyogenesis in the failing heart. However, teratoma/tumour formation originating from undifferentiated iPSCs contaminating the graft is a critical concern for clinical application. Here, we hypothesized that brentuximab ve...
Autores principales: | Sougawa, Nagako, Miyagawa, Shigeru, Fukushima, Satsuki, Kawamura, Ai, Yokoyama, Junya, Ito, Emiko, Harada, Akima, Okimoto, Kaori, Mochizuki-Oda, Noriko, Saito, Atsuhiro, Sawa, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829260/ https://www.ncbi.nlm.nih.gov/pubmed/29487310 http://dx.doi.org/10.1038/s41598-018-21923-8 |
Ejemplares similares
-
Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application
por: Ito, Emiko, et al.
Publicado: (2019) -
Eliminating residual iPS cells for safety in clinical application
por: Masuda, Shigeo, et al.
Publicado: (2015) -
hiPSC-Derived Cardiac Tissue for Disease Modeling and Drug Discovery
por: Li, Junjun, et al.
Publicado: (2020) -
Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells
por: Takeda, Maki, et al.
Publicado: (2018) -
Pivotal Role of Non-cardiomyocytes in Electromechanical and Therapeutic Potential of Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissue
por: Iseoka, Hiroko, et al.
Publicado: (2018)